PriceTargets.com logo

NASDAQ:MDVL - MedAvail Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$14.15 As of 03/1/2021 12:13 PM ET
▲ +0.26 (1.87%)
1 month | 3 months | 12 months
Get New MedAvail Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDVL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDVL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for MedAvail in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $14.15.
Buy
The current consensus among 2 investment analysts is to buy stock in MedAvail.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/14/2020Lake Street CapitalInitiated CoverageBuyLow
i
12/14/2020CowenInitiated CoverageOutperformHigh
i
(Data available from 3/1/2016 forward)
MedAvail logo
MedAvail Holdings, Inc. operates as a technology enabled pharmacy company that embeds automated pharmacy services directly into clinics and other points of care through its proprietary technology. The company provides turnkey services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations. It also operates SpotRx, a telehealth platform that delivers remote pharmacist consultations through an on-site dispensing kiosk, supplemented with home delivery. MedAvail Holdings, Inc. is based in Mississauga, Canada.
Read More

Today's Range

Now: $14.15
$13.95
$14.34

50 Day Range

MA: $14.00
$12.51
$17.15

52 Week Range

Now: $14.15
$8.89
$46.20

Volume

703 shs

Average Volume

134,258 shs

Market Capitalization

$14.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of MedAvail?

The following equities research analysts have issued research reports on MedAvail in the last year: Cowen Inc, and Lake Street Capital.
View the latest analyst ratings for MDVL.

What is the current price target for MedAvail?

0 Wall Street analysts have set twelve-month price targets for MedAvail in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for MedAvail in the next year.
View the latest price targets for MDVL.

What is the current consensus analyst rating for MedAvail?

MedAvail currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDVL will outperform the market and that investors should add to their positions of MedAvail.
View the latest ratings for MDVL.

What other companies compete with MedAvail?

Other companies that are similar to MedAvail include Pulmatrix, Guardion Health Sciences, Akari Therapeutics, Appili Therapeutics, Soligenix, Trevi Therapeutics, Cumberland Pharmaceuticals, Regulus Therapeutics, Forward Pharma A/S, NovaBay Pharmaceuticals, Bio-Path, Generex Biotechnology, Newron Pharmaceuticals, Addex Therapeutics and Ceapro.

How do I contact MedAvail's investor relations team?

MedAvail's physical mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company's listed phone number is 905-812-0023 and its investor relations email address is [email protected] The official website for MedAvail is www.medavail.com.